Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial
Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial
复制标题
DOI：
10.1002/mnfr.201100673
复制
发表时间：
2012-05-01
影响因子：
5.2
通讯作者：
Carlos Espin, Juan
中科院分区：
文献类型：
--
作者：
Tome-Carneiro, Joao;Gonzalvez, Manuel;Carlos Espin, Juan
范围白藜芦醇作为人类饮食的一部分的心脏保护作用尚不清楚。我们的目的是研究含有8 mg白藜芦醇的葡萄补充剂对氧化低密度脂蛋白（LDLox）、载脂蛋白B（ApoB）和血脂对接受他汀类药物治疗的患者在一级心血管疾病预防（PCP）中的影响。方法和结果进行了一项三盲、随机、安慰剂对照试验。75名患者（三个平行组）每天服用一粒胶囊（350 mg），持续6个月，胶囊中含有富含白藜芦醇的葡萄提取物（GE-RES，Stilvid（R））、葡萄提取物（GE，多酚含量相似，但不含白藜芦醇）或安慰剂（麦芽糊精）。6个月后，安慰剂组未观察到变化，GE组仅LDL胆固醇（LDLc）降低2.9%（p = 0.013）。相比之下，Stilvid（R）组的LDLc（-4.5%，p = 0.04）、ApoB（-9.8%，p = 0.014）、LDLox（-20%，p = 0.001）和LDLox/ApoB（-12.5%，p = 0.000）降低，而非HDLc（总致动脉粥样硬化胆固醇负荷）/ApoB比值升高（8.5%，p = 0.046）。肝、甲状腺和肾功能未观察到变化。在任何患者中均未观察到不良反应。结论GE-RES可降低PCP患者的动脉粥样硬化指标，并可能在金标准药物之外发挥额外的心脏保护作用。白藜芦醇在GE中的存在是实现这些效果所必需的。
Scope The cardioprotective role of resveratrol as part of the human diet is not yet clear. Our aim was to investigate the effect of a grape supplement containing 8 mg resveratrol in oxidized LDL (LDLox), apolipoprotein-B (ApoB), and serum lipids on statin-treated patients in primary cardiovascular disease prevention (PCP). Methods and results A triple-blind, randomized, placebo-controlled trial was conducted. Seventy-five patients (three parallel arms) consumed one capsule (350 mg) daily for 6 months containing resveratrol-enriched grape extract (GE-RES, Stilvid (R)), grape extract (GE, similar polyphenolic content but no resveratrol), or placebo (maltodextrin). After 6 months, no changes were observed in the placebo group and only LDL cholesterol (LDLc) decreased by 2.9% (p = 0.013) in the GE group. In contrast, LDLc (-4.5%, p = 0.04), ApoB (-9.8%, p = 0.014), LDLox (-20%, p = 0.001), and LDLox/ApoB (-12.5%, p = 0.000) decreased in the Stilvid (R) group, whereas the ratio non-HDLc (total atherogenic cholesterol load)/ApoB increased (8.5%, p = 0.046). No changes were observed in hepatic, thyroid, and renal function. No adverse effects were observed in any of the patients. Conclusion This GE-RES reduced atherogenic markers and might exert additional cardioprotection beyond the gold-standard medication in patients from PCP. The presence of resveratrol in the GE was necessary to achieve these effects.